Results 61 to 70 of about 77,820 (264)
Chronic Prurigo of Nodular Type: A Review
Prurigo nodularis (PN) is a subtype of chronic prurigo presenting single to multiple symmetrically distributed, hyperkeratotic and intensively itching papules and nodules.
Claudia Zeidler +5 more
doaj +1 more source
Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa
ABSTRACT Dapsone is a potent antibacterial agent used as a first‐line treatment for leprosy and employed also as an anti‐inflammatory agent. Additionally, dapsone is used for a variety of other cutaneous conditions. Herein, we report a case of intermediate junctional epidermolysis bullosa that improved significantly with oral 4,4’‐diamino‐diphenyl ...
Shiho Mori +2 more
wiley +1 more source
The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous ...
Lina Renkhold +13 more
doaj +1 more source
Effect of Sertraline on Uremic Pruritus Improvement in ESRD Patients
Background. Although uremic pruritus is a common and upsetting problem of chronic kidney disease, there is no approved treatment for it. This study was undertaken to find the efficiency of sertraline as a possible treatment for uremic pruritus. Methods.
Mansor Shakiba +4 more
doaj +1 more source
Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos +2 more
wiley +1 more source
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge +5 more
wiley +1 more source
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won +11 more
wiley +1 more source
PIEZO1 channels in cutaneous free nerve endings: novel insights into itch-scratch-mechanisms
Manuel Pedro Pereira +2 more
doaj +1 more source
Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio +8 more
wiley +1 more source
Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab
ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle +7 more
wiley +1 more source

